Blood Volume Assessment in COVID-19 and Bacterial Sepsis (BVAC19)
Blood Volume, Components and Capillary Leak in ICU Patients With SARS-CoV-2 and Bacterial Infections
Sponsor: Daxor Corporation
A observational or N/A phase clinical study on Acute Respiratory Distress Syndrome and Bacterial Infections, this trial is completed. The trial is conducted by Daxor Corporation and has accumulated 8 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Oct 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Nov 2022 — Oct 2023 [monthly]
Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Recruiting
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daxor Corporation
- NYU Langone Health
For direct contact, visit the study record on ClinicalTrials.gov .